FDA deal with drugmakers raises user fees 6 percent
Drugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing the drug-approval process through fiscal 2017.

FDA chemist near plea over insider trading charges
WASHINGTON (Reuters) - A Food and Drug Administration chemist and his son accused of making millions of dollars with inside information about drug approvals are close to reaching plea agreements, according to court papers.

FDA, industry reach generic drug fee agreement
WASHINGTON (Reuters) - U.S. regulators and generic drugmakers have reached a compromise agreement for a user-fee program that would require the companies to pay some $299 million in the first year to accelerate drug approvals.